Monoclonal gammopathy of renal significance (MGRS) is a pathogenic entity associated with significant morbidity, mainly end stage kidney disease. Proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID), a type of MGRS, is a specific disease resulting from the deposition of a monoclonal immunoglobulin leading to kidney damage. While PGNMID has been recognized to lead to end-stage kidney disease, until recently there was no evidence to guide treatment. Here, we report a case of a patient with PGNMID who responded well to daratumumab.
LeungNBridouxFBatumanV, et alThe evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol2019; 15(1): 45–59.
2.
LeungNBridouxFHutchisonCA, et alMonoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood2012; 120(22): 4292–4295.
3.
NasrSHMarkowitzGSStokesMB, et alProliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int2004; 65(1): 85–96.
4.
GumberRCohenJBPalmerMB, et alA clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int2018; 94(1): 199–205.
5.
ZandLRajkumarSVLeungN, et alSafety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits. J Am Soc Nephrol2021; 32(5): 1163–1173.
6.
KastritisETheodorakakouFRoussouM, et alDaratumumab-based therapy for patients with monoclonal gammopathy of renal significance. Br J Haematol2021; 193(1): 113–118.
7.
AlmaaniSParikhSVSatoskarAA, et alDaratumumab in patients with bortezomib-refractory proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int Rep2021; 6(8): 2203–2206.
